Enhancing topical ruxolitinib delivery via emulgel for vitiligo: formulation development, in vitro release, skin permeation, and mechanistic effects on melanogenesis

February 14, 2026Chemical Papers

View at Publisher

Ask AI

Bookmark

Share

Key Points

Topical ruxolitinib delivery significantly improved melanogenesis when using an emulgel formulation, leading to better outcomes in vitiligo treatment.
Release studies indicated a controlled in vitro release profile over a 24-hour period, establishing effective drug availability.
Skin permeation tests demonstrated enhanced absorption of ruxolitinib through emulgel compared to conventional formulations, reaching deeper layers of skin.
These findings highlight the potential of emulgel formulations for optimizing drug delivery in dermatological therapies, warranting further clinical validation.

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Observational analysis shows enhanced melanin production with emulgel-formulated ruxolitinib in vitiligo, suggesting improved treatment options.

No takes yet. Share an insight, caveat, or question.

Shelke et al. (2026) studied this question.

View at Publisher

Ask AI

Bookmark

Share